Kornimate/medical-research-clean huggingface dataset:
predicting rehabilitation outcomes in bilingual aphasia using computational modeling

Conditions: Aphasia

Summary: the purpose of this investigation is to implement a computational model that can predict and optimize training and cross-language generalization patterns for bilingual persons with aphasia (bpa). the proposed work will determine the best possible treatment program for each individual patient even before they are rehabilitated. in addition, the computational model allows specification of variables such as age of acquisition, language exposure/proficiency, impairment and their systematic influence on a range of language rehabilitation outcomes.


Eligibility criteria:
inclusion criteria: * any number of years of education * bilingual: speaking both spanish and english (or chinese and english) with any degree of language proficiency prior to stroke * aphasia secondary to a left-hemisphere stroke (diagnosed by a neurologist on the basis of clinical ct/mri imaging or medical reports) * aphasia resulting from stroke or dementia * naming deficits must be present with concurrent lexical/semantic impairment * visual and auditory acuity sufficient for all assessment and treatment procedures * ability to understand study and follow study procedures for the entire length of the study exclusion criteria: * premorbid history of speech/language disorder * proficient in more than just spanish and english (or chinese and english) * overt, behaviorally noticeable, attentional limitations that interfere with completing the experimental tasks * active medical disease that may compromise participation (e.g., cancer undergoing acute treatment, unstable diabetes, renal or hepatic insufficiency, fluctuating systemic immunological disease such as systemic lupus erythematosis, etc.) * currently taking medications that are known to exert significant effects on cognitive processes, such as neuroleptics, steroids, anticholinesterase inhibitors, etc. * current drug or alcohol use or dependence that would interfere with adherence to study requirements, in the opinion of the principal investigator * inability or unwillingness of individual to give written informed consent * diagnosed with mental illness other than active depression * neurological condition other than that which resulted in aphasia

Keywords: aphasia bilingualism language therapy rehabilitation of speech and language disorders speech-language pathology
hfs (high-fiber supplement) in ms (multiple sclerosis)

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is an autoimmune disease directed against the central nervous system (cns). recent studies have indicated that changes in the gut microbiota are associated with disease initiation and progression. the reduction of bacterial taxa involved in producing health-promoting metabolites, such as short-chain fatty acids (scfas), has been reported in ms patients. scfas play an important role in the suppression of inflammation. the levels of scfas in the blood of ms patients are significantly reduced when compared to those of healthy controls. since the intake of dietary fiber increases the growth of scfa-producing bacteria, we investigated the effect of a high-fiber supplement (hfs) on gut bacteria and immunological parameters in ms patients.

our collaborator, dr. liping zhao, developed a high-fiber supplement (hfs), nbt-nm108. his recent study has suggested an association between intake of nbt-nm108 and increased abundance of short-chain fatty acid (scfa)-producing gut bacteria. recent studies have suggested that relapsing-remitting multiple sclerosis (rrms) is associated with gut dysbiosis, alteration of gut bacteria, and decreased production of scfas. therefore, we have investigated the effect of nbt-nm108 on rrms-associated gut dysbiosis and the cytokines produced by immune cells. seven patients were enrolled, and their stool samples were collected before the treatment with nbt-nm108 (baseline). three patients from the enrolled patients consumed nbt-nm108 three times a day at 60 g/day for 8 weeks. two patients further consumed nbt-nm108 for four more weeks (a total of 12 weeks). stool and blood samples were collected at 3 time points (baseline, 8 weeks post-nbt-nm108, and 12 weeks post-nbt-nm108). we have investigated the effect of nbt-nm108 on gut microbiota and immune parameters involved in ms.

Eligibility criteria:
inclusion criteria: patients with the first demyelinating event who meet the mcdonald criteria for relapsing remitting ms. exclusion criteria: 1. primary or secondary progressive ms. 2. patients with autoimmune comorbidities. 3. having received prior chemotherapy. 4. having received dimethylfumarate (dmf). 5. pregnant women. 6. cognitively impaired. 7. antibiotic use within last 6 months. 8. probiotic use within 2 months. 9. self-reported allergy or intolerance to any ingredients in the fiber supplement. 10. self-reported or diagnosed gastrointestinal symptoms, disorders or adenomas. 11. active or history of malignant tumors.

Keywords: high-fiber supplement
a trial comparing gsk1349572 50mg once daily to raltegravir 400mg twice daily

Conditions: Infection, Human Immunodeficiency Virus I

Summary: the purpose of this trial is to assess the non-inferior antiviral activity of gsk1349572 50 mg once daily versus ral 400mg twice daily over 48 weeks; non-inferiority will also be tested at week 96. both gsk1349572 and ral will be given in combination with fixed-dose dual nrti therapy (abc/3tc or tdf/ftc). this study will be conducted in hiv-1 infected art-naïve adult subjects.

ing113086 is a phase 3 randomized, double-blind, double dummy, active-controlled, multicenter, study conducted in approximately 788 hiv-1 infected art-naïve subjects. subjects will be randomized 1:1 one of the following treatment arms: 1. gsk1349572 50 mg once daily (approximately 394 subjects) + fixed-dose dual nrti therapy (either abc/3tc or tdf/ftc) or 2. 400 mg ral twice daily (approximately 394 subjects) + fixed-dose dual nrti therapy (either abc/3tc or tdf/ftc) analyses will be conducted at 48 weeks and 96 weeks. subjects randomized to receive gsk1349572 and who successfully complete 96 weeks of treatment will continue to have access to gsk1349572 through the study until either it is locally available, as long as they continue to derive clinical benefit. viiv healthcare is the new sponsor of this study, and glaxosmithkline is in the process of updating systems to reflect the change in sponsorship

Eligibility criteria:
inclusion criteria: * screening plasma hiv-1 rna ≥1000 c/ml * antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of hiv-1 infection) * ability to understand and sign a written informed consent form * willingness to use approved methods of contraception to avoid pregnancy (women of child bearing potential only) * age equal to or greater than 18 years exclusion criteria: * women who are pregnant or breastfeeding; * active center for disease and prevention control (cdc) category c disease * moderate to severe hepatic impairment * anticipated need for hcv therapy during the study * allergy or intolerance to the study drugs or their components or drugs of their class * malignancy within the past 5 years * treatment with an hiv-1 immunotherapeutic vaccine within 90 days of screening * treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of screening * exposure to an agent with documented activity against hiv-1 in vitro or an experimental vaccine or drug within 28 days of first dose of study medication * primary viral resistance in the screening result * verified grade 4 laboratory abnormality * alt \>5 xuln * alt ≥ 3xuln and bilirubin ≥ 1.5xuln (with \>35% direct bilirubin); * estimated creatinine clearance \<50 ml/min * recent history (≤3 months) of upper or lower gastrointestinal bleed

Keywords: integrase inhibitor hiv infection raltegravir gsk1349572
divided drug delivery

Conditions: Hospitalized for Voluntary Drug Intoxication

Summary: this study will evaluate the efficacy of an advice with a weekly divided drug delivery, compared to an usual monthly delivery in the prevention of voluntary drug intoxications repeated.


Eligibility criteria:
inclusion criteria: * men and women between 18 and 65 years. * hospitalized after a voluntary drug intoxication. * history of two voluntary drug intoxications at least. * person registered for social security. * signed free consent. exclusion criteria: * patients under treatment for opiate split * acute or chronicgoing wild. * cognitive problems hindering understanding of questionnaires * persons targeted by articles l1121-5 to l1121-8 of csp

Keywords: imv : voluntary drug intoxications drug divided prescription
berlin-brandenburg pregnancy cohort

Conditions: Preeclampsia; Pregnancy Complications; Diabetes Mellitus in Pregnancy

Summary: this study will investigate the interplay of different immune cells and placental cells as well as their potential for the development of pregnancy complications. in particular, the translation of the uteroplacental syndrome into a maternal syndrome, considered in the multifactorial pregnancy disorder preeclampsia, will be investigated. immune cell subtypes are causally involved in the formation and translation of preeclampsia by inducing an endothelial dysfunction which leads to cardiovascular damage.


Eligibility criteria:
inclusion criteria: * healthy pregnant women after giving informed consent * pregnant with diagnosis of preeclampsia, gestational hypertension or gestational diabetes exclusion criteria: * infections * alcohol and drug abuse * manifest and chronic diseases
study of safety and efficacy of pembrolizumab and chemotherapy in participants with newly diagnosed classical hodgkin lymphoma (chl) (mk-3475-c11/keynote-c11)

Conditions: Classical Hodgkin Lymphoma

Summary: the purpose of this study is to evaluate the safety and efficacy of pembrolizumab (mk-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation. the primary hypothesis of the study is that the complete response (cr) rate at the end of study intervention according to lugano 2014 response criteria is higher than conventional chemotherapy.


Eligibility criteria:
inclusion criteria: the main inclusion criteria include, but are not limited to the following: * has a histologically confirmed diagnosis of ann arbor stage iii or iv classical hodgkin lymphoma (chl). stage i and ii participants may be enrolled, but must have at least one national comprehensive cancer network (nccn) unfavorable risk factor per protocol * has measurable 2-fluorodeoxyglucose (fdg)-avid disease based on investigator assessment according to lugano 2014 response criteria * has not received prior radiation therapy, chemotherapy, immunotherapy, or other systemic therapy for the treatment of chl before the first dose of study intervention * has an eastern cooperative oncology group (ecog) performance status of 0 to 1 assessed within 7 days before the start of study intervention exclusion criteria: the main exclusion criteria include, but are not limited to the following: * has confirmed nodular lymphocyte-predominant hodgkin lymphoma (hl) * has an uncontrolled intercurrent cardiovascular illness * has received prior therapy with an anti-programmed cell death 1 protein (pd-1), anti-programmed cell death ligand 1 protein (pd-l1), or anti- programmed cell death ligand 2 protein (pd-l2) agent or with an agent directed to another stimulatory or coinhibitory t-cell receptor * has received or is expected to receive a live or live-attenuated vaccine within 30 days before the first dose of study intervention * is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention * has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication * has a known additional malignancy that is progressing or has required active treatment within the past 5 years * has radiographically detectable central nervous system metastases and/or carcinomatous meningitis * has an active autoimmune disease that has required systemic treatment in past 2 years * has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * has a history or current evidence of pulmonary fibrosis * has had an allogenic tissue/solid organ transplant

Keywords: programmed cell death 1 (pd-1, pd1) programmed cell death-ligand 1 (pd-l1, pdl1) programmed cell death-ligand 2 (pd-l2, pdl2)
current incidence and treatments performed of fractures of the acetabulum and pelvis in france in 2013

Conditions: Acetabulum; Fractures

Summary: fractures of the acetabulum and pelvis are serious injuries to vital prognostic can play in cases of severe bleeding. in all cases the functional is a major issue with a potential reach of walking ability and maintaining the seated and standing positions. the treatment of such lesions requires management to a specialist, or the ability to use such centers for advice or transferring patients. this organization was recommended after the symposium of the french society of orthopedic surgery (sofcot) in 2009. with the aging population, the incidence and clinical features of these fractures have evolved to worsening the functional prognosis. club basin acetabulum, body sofcot, wants to achieve an observational study assessing needs and practices at national and regional level. the long-term objective is to propose a regional organization of care of these patients in order to reduce morbidity and mortality associated.

fractures of the acetabulum and pelvis are serious injuries to vital prognostic can play in cases of severe bleeding. in all cases the functional is a major issue with a potential reach of walking ability and maintaining the seated and standing positions. the treatment of such lesions requires management to a specialist, or the ability to use such centers for advice or transferring patients. this organization was recommended after the symposium of the french society of orthopedic surgery (sofcot) in 2009. with the aging population, the incidence and clinical features of these fractures have evolved to worsening the functional prognosis. club basin acetabulum, body sofcot, wants to achieve an observational study assessing needs and practices at national and regional level. the long-term objective is to propose a regional organization of care of these patients in order to reduce morbidity and mortality associated. format of research retrospective observational study of sniiram data on hospitalizations for broken pelvis and acetabulum (ccam codes s32.40 / s32.41 / s32.30 / s32.31 / s32.10 / s32.11 / s32.50 / s32 .51 / s32.70 / s32.71 / s32.80 / s32.81), with collection of the following data: * patient demographics: age, sex, comorbidities (drg coding), place of residence. * length of hospital stay * treatment undertaken: ccam coding during hospitalization * mortality at 30 days and 1 year.

Eligibility criteria:
inclusion criteria: * all patients exclusion criteria: * no exclusion criteria

Keywords: prevalence surgery treatments
"living an active life with osteoporosis" - a digital patient education program on osteoporosis. a feasibility/pilot study as part of the patos project (patient education in osteoporosis).

Conditions: Osteoporosis

Summary: in this feasibility and pilot study, the investigators aim to evaluate the effectiveness and safety of a digital patient education program for individuals with osteoporosis. the study involves a 5-week intervention period during which participants will have access to the digital education program. patients will be assessed both before and after the intervention. the digital patient education program comprises eight modules covering essential topics related to osteoporosis self-care. the program includes both psychoeducation and support for behavioral changes. patients will progress through the program at their own pace. the name of the digital patient education program is: program is: "att leva ett aktivt liv med benskörhet" (translated to english "living an active life with osteoporosis")


Eligibility criteria:
inclusion criteria: * osteoporosis diagnosis with or without a previous low-energy fracture * age \> 50 years * women and men * basic computer skills exclusion criteria: * patients with difficulty understanding the swedish language to the extent that they cannot comprehend the content of the patient education program. * cognitive impairment/dementia where the patient is not deemed to understand the implications of study participation

Keywords: osteoporosis patient education ehealth self-care
ats907 ph2a open-label dose-ranging safety and tolerability in primary open angle glaucoma (poag) and ocular hypertension (oht) subjects

Conditions: Primary Open Angle Glaucoma; Ocular Hypertension

Summary: this single-site, dose-escalation study will evaluate safety and tolerability of increasing concentrations of ats907 in 12 subjects with primary open angle glaucoma and/or ocular hypertension


Eligibility criteria:
inclusion criteria: * 18 years of age or greater * diagnosis of open angle glaucoma or ocular hypertension in both eyes * corrected visual acuity in each eye +1.0 logmar or better by early treatment diabetic retinopathy study (edtrs) in each eye (equivalent to 20/200) * must be willing to discontinue the use of all ocular hypotensive medications in both eyes prior to and during the entire course of the study exclusion criteria: ophthalmic (in either eye): * glaucoma: pseudoexfoliation, steroid induced, pigment dispersion glaucoma, and or history of angle closure. previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s). refractive surgery in study eye * cataract surgery and or other intraocular surgery within one month prior to screening in either eye * history within 3 months prior to screening of clinically significant moderate or severe chronic or active ocular infection, inflammation, blepharitis, dermatitis, uveitis or conjunctivitis * clinically significant corneal dystrophy, epithelial and or endothelial disease, corneal irregularities and or scarring such that reliable applanation tonometry would prevented * contact lens wear during the duration of the study * clinically significant ocular disease (e.g., diabetic retinopathy, macular degeneration, or uveitis) which might interfere or progress during the study
safety and immunogenicity of v114 in children infected with human immunodeficiency virus (hiv) (v114-030/pneu-way ped)

Conditions: Pneumococcal Infections

Summary: this is a study of v114 in children infected with hiv. participants will be randomly assigned in a 1:1 ratio to receive either v114 or prevnar 13™ followed 8 weeks later by a single dose of pneumovax™23. the primary objectives of this study are to evaluate the safety and tolerability of v114 in children 6 to 17 years of age inclusive infected with hiv and to evaluate the anti-pneumococcal polysaccharide (pnps) serotype-specific immunoglobulin g (igg) geometric mean concentrations (gmcs) at 30 days following vaccination with v114 or prevnar 13™ by each vaccination group. there are no formal hypotheses.


Eligibility criteria:
inclusion criteria: * male or female between the ages of 6 and 17 years (inclusive) infected with hiv and has a cluster of differentiation 4+ (cd4+) t-cell count ≥200 cells/µl and plasma hiv ribonucleic acid (rna) \<50,000 copies/ml * is pneumococcal conjugate vaccine (pcv) naïve, previously vaccinated with a \<13-valent pcv, partially vaccinated with prevnar 13™, or has a history of previous prevnar 13™ vaccination ≥3 years before visit 2 (day 1) * is pnps vaccine naïve or has a history of 1 previous pnps vaccination ≥5 years before visit 2 (day 1) * female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last dose of the study vaccine. exclusion criteria: * history of world health organization (who) hiv classification of clinical stage 4 disease within the past 12 months * history of invasive pneumococcal disease * known hypersensitivity to any vaccine component * known or suspected congenital immunodeficiency (other than hiv infection), functional or anatomic asplenia, or history of autoimmune disease * bleeding disorder contraindicating intramuscular vaccinations * history of malignancy ≤5 years prior to signing informed consent/assent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer * female participant: positive urine or serum pregnancy test * expect to receive any pneumococcal vaccine during the study outside of the protocol * receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease * received a blood transfusion or blood products within 6 months of enrollment * participated in another clinical study of an investigational product within 2 months of enrollment * current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence

Keywords: pneumococcal conjugate vaccine (pcv), 15-valent, 22f, 33f
dietary nitrate and exercise to augment exercise training benefits in subjects with dm+pad

Conditions: Peripheral Arterial Disease; Type II Diabetes Mellitus

Summary: the hypothesis of this proposal is that in subjects with type ii diabetes mellitus (t2d) and peripheral arterial disease (pad) with intermittent claudication (ic), regular consumption of a high nitrate supplement which raises plasma nitrite, in conjunction with 12 weeks of supervised exercise training at the limb ischemic threshold (set) will produce a greater clinical benefit (increases in claudication onset time \[cot\] and peak walking time \[pwt\] relative to a group with the same exercise training but supplemented with placebo .this study is essentially exploratory in nature and designed to provide us with information to adequately develop power and execute a larger study. we have previously seen benefits from nitrate supplementation on function in pad.


Eligibility criteria:
inclusion criteria: * peripheral arterial disease (abi of less than 0.9) * diagnosed type ii diabetes * intermittent claudication for 3 or more months exclusion criteria: * individuals with known alcohol or drug abuse problems * individuals who have suffered a heart attack or stroke, or have changes on a resting ecg, in the last 3 months * those classified as american heart association class d * gangrene, impending limb loss or osteomyelitis * lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months of enrollment * severe peripheral neuropathy * any condition other than pad that limits walking * chest pain during treadmill exercise which appears before the onset of claudication, or \>3mm st depression during exercise * subjects taking nitrates or nitroglycerin products * must not be taking protein pump inhibitor medications

Keywords: cardiovascular diseases vascular diseases arterial occlusive diseases diabetes exercise functional capacity